Related Experiment Video
Updated: May 8, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications
Hiba Mechahougui1, James Gutmans1, Roumaïssa Gouasmi2
1Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland.
Abstract:
BRAF mutations are critical drivers in cancers such as melanoma, colorectal cancer, and non-small-cell lung cancer. The most common mutation, BRAF V600E, is a key therapeutic target. Targeted treatments with BRAF and MEK inhibitors have significantly improved progression-free and overall survival in melanoma patients. However, in cancers like metastatic colorectal cancer, BRAF mutations are associated with poor outcomes due to aggressive disease behavior and resistance to conventional chemotherapy. Despite progress, resistance to BRAF/MEK inhibitors remains a major challenge, often driven by secondary mutations in the mitogen-activated protein kinase (MAPK) pathway, activation of alternative pathways such as phosphoinositide 3-kinases (PI3Ks)/protein kinase B (AKT), or changes in the tumor microenvironment. These challenges have motivated ongoing research into combining BRAF inhibitors with immunotherapies to enhance and prolong treatment effectiveness. Future research must also account for the role of the cancer's tissue of origin, as the biological context significantly influences response to targeted therapies, highlighting the need for a deeper understanding of tumor biology, micro-environment, and genetics.
Insights
BRAF V600E mutations drive cancers like melanoma. Targeted therapies improve survival, but resistance necessitates exploring combinations with immunotherapy and understanding tumor biology.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- BRAF mutations, particularly BRAF V600E, are key drivers in various cancers, including melanoma, colorectal, and non-small-cell lung cancer.
- Targeted therapies inhibiting BRAF and MEK have shown efficacy, especially in melanoma, improving patient survival rates.
Purpose of the Study:
- To review the role of BRAF mutations in cancer and the challenges associated with targeted therapies.
- To explore emerging strategies, including immunotherapy combinations, to overcome treatment resistance.
- To emphasize the importance of tumor origin and microenvironment in therapeutic response.
Main Methods:
- Literature review of BRAF mutations in cancer.
- Analysis of targeted therapy mechanisms and resistance pathways.
- Exploration of combination strategies and future research directions.
Main Results:
- BRAF V600E is a significant therapeutic target, with inhibitors improving outcomes in melanoma.
- Resistance to BRAF/MEK inhibitors arises from secondary mutations, alternative pathway activation (PI3K/AKT), and tumor microenvironment changes.
- Metastatic colorectal cancer with BRAF mutations shows poor prognosis and chemoresistance.
Conclusions:
- BRAF inhibitors offer benefits but face resistance challenges.
- Combining BRAF inhibitors with immunotherapy is a promising strategy to enhance treatment efficacy.
- Understanding cancer-specific biology, including tissue of origin and tumor microenvironment, is crucial for optimizing targeted therapies.
